Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease

Kidney International

Volumn 87, Issue 5, 2015, Pages 1039-1045

  De Oliveira, Rodrigo A ^a,b   Barreto, Fellype C ^c   Mendes, Monique ^a   Dos Reis, Luciene M ^a   Castro, João Henrique ^d   Britto, Zita Maria L ^a   Marques, Igor D B ^a   Carvalho, Aluizio B ^e   Moysés, Rosa M ^a,f   Jorgetti, Vanda ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSIDADE NOVE DE JULHO   (Brazil)

Author keywords

chronic kidney disease; diabetes; mineral metabolism; peritoneal dialysis; vascular calcification

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALKALINE PHOSPHATASE; BETA CATENIN; CALCITRIOL; DEOXYPYRIDINOLINE; PARATHYROID HORMONE; PHOSPHATE; SCLEROSTIN; WNT PROTEIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ADULT; ADYNAMIC BONE DISEASE; AGE; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE MINERALIZATION; BONE TURNOVER; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENDER; HEMODIALYSIS; HUMAN; MALE; MINERAL METABOLISM; MORPHOMETRICS; OSSIFICATION; OSTEOBLAST; PATHOGENESIS; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENAL OSTEODYSTROPHY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TREATMENT DURATION; BLOOD; BONE; BONE REMODELING; CROSS-SECTIONAL STUDY; GENETIC MARKER; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICAL MODEL;

ADULT; BIOMARKERS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC MARKERS; HUMANS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL OSTEODYSTROPHY; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84929128859     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.372     Document Type: Article

References (40)

1. Carmen Sánchez M, Auxiliadora Bajo M, Selgas R et al. Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 2000; 36: 953-961.
2. Joffe P, Heaf JG, Hyldstrup L. Osteocalcin: a non-invasive index of metabolic bone disease in patients treated by CAPD. Kidney Int 1994; 46: 838-846.
3. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in endstage renal failure-an evolving disorder. Kidney Int 1993; 43: 436-442.
4. Torres A, Lorenzo V, Hernández D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-S130.
6. Kurz P, Tsobanelis T, Brunkhorst R et al. Calcium kinetic studies in patients on CAPD: improvement of secondary hyperparathyroidism without concomitant improvement of calcium turnover. Perit Dial Int 1997; 17: 59-65.
7. Parfitt AM. Misconceptions (3): calcium leaves bone only by resorption and enters only by formation. Bone 2003; 33: 259-263.
8. Barreto FC, Barreto DV, Moysés RMA et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777.
9. Delanaye P, Souberbielle J-C, Lafage-Proust M-H et al. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts. Nephrol Dial Transplant 2013; 29: 997-1004.
10. Parker CR, Blackwell PJ, Freemont AJ et al. Biochemical measurements in the prediction of histologic subtype of renal transplant bone disease in women. Am J Kidney Dis 2002; 40: 385-396.
11. Urena P, Hruby M, Ferreira A et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512.
12. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882.
13. Cejka D, Jäger-Lansky A, Kieweg H et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 226-230.
14. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320.
15. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1-201.
16. Sanchez CP. Adynamic bone revisited: is there progress? Perit Dial Int 2006; 26: 43-48.
17. Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73: 1345-1354.
18. Haris A, Sherrard DJ, Hercz G. Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int 2006; 70: 931-937.
19. Alikhani M, Alikhani Z, Boyd C et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007; 40: 345-353.
20. Van Driel M, Koedam M, Buurman CJ et al. Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization. J Cell Biochem 2006; 99: 922-935.
21. Gennari L, Merlotti D, Valenti R et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 1737-1744.
22. Dias CB, Dos Reis LM, Caparbo VF et al. Decreased in vitro osteoblast proliferation and low turnover bone disease in nonuremic proteinuric patients. Kidney Int 2007; 71: 562-568.
23. Zhou S, Leboff MS, Waikar SS et al. Vitamin D metabolism and action in human marrow stromal cells: effects of chronic kidney disease. J Steroid Biochem Mol Biol 2013; 136: 342-344.
24. Sabbagh Y, Graciolli FG, O'Brien S et al. Repression of osteocyte Wnt/bcatenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012; 27: 1757-1772.
25. Kuhlmann MK. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif 2010; 29: 137-144.
26. Ferreira JC, Ferrari GO, Neves KR et al. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease-role of sclerostin? PloS One 2013; 8: 79721.
27. Sahin G, Kirli I, Sirmagul B et al. Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients. Int Urol Nephrol 2009; 41: 989-996.
28. Gracia-Iguacel C, Gallar P, Qureshi AR et al. Vitamin D deficiency in dialysis patients: effect of dialysis modality and implications on outcome. J Ren Nutr 2010; 20: 359-367.
29. Rudnicki M, Kerschbaum J, Hausdorfer J et al. Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin d. Perit Dial Int 2010; 30: 541-548.
30. Bindal ME, Taskapan H. Hypovitaminosis D and insulin resistance in peritoneal dialysis patients. Int Urol Nephrol 2011; 43: 527-534.
31. Adragao T, Pires A, Birne R et al. A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrol Dial Transplant 2009; 24: 997-1002.
32. Cejka D, Marculescu R, Kozakowski N et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014; 99: 248-255.
33. Bervoets ARJ, Spasovski GB, Behets GJ et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003; 41: 997-1007.
34. Pelletier S, Vilayphiou N, Boutroy S et al. Bone microarchitecture is more severely affected in patients on hemodialysis than in those receiving peritoneal dialysis. Kidney Int 2012; 82: 581-588.
35. Hernandez JD, Wesseling K, Pereira R et al. Technical approach to iliac crest biopsy. Clin J Am Soc Nephrol 2008; 3(Suppl 3): S164-S169.
36. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610.
37. Dos Reis LM, Batalha JR, Munoz DR et al. Brazilian normal static bone histomorphometry: effects of age, sex, and race. J Bone Miner Metab 2007; 25: 400-406.
38. Vedi S, Compston JE, Webb A et al. Histomorphometric analysis of dynamic parameters of trabecular bone formation in the iliac crest of normal British subjects. Metab Bone Dis Relat Res 1983; 5: 69-74.
39. Denton J, Freemont AJ, Ball J. Detection and distribution of aluminium in bone. J Clin Pathol 1985; 37: 136-142.
40. Gomes SA, dos Reis LM, de Oliveira IB et al. Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate: an improved method for immunohistochemistry. J Bone Miner Metab 2008; 26: 110-113.